Literature DB >> 51062

Thrombosis and intracranial tumors.

M C Kayser-Gatchalian, K Kayser.   

Abstract

334 necropsy reports of intracranial neoplasm from an autopsy material over 13 years were reviewed to study the relationship of intracranial tumors to vascular thrombosis. The incidence of venous thrombosis in intracranial tumors was found to be 27.5% while that of a control group without malignancies taken at random from the autopsy material was 17%. The difference gives a statistical significance of P less than or equal to 0.05. The parameters of sex, surgical intervention, the malignancy and the histological type of the tumor apparently dod not affect thrombus formation to a statistically significant degree. There is increased thrombosis frequency with increasing age. The presence of hemiparesis or hemiparalysis does not affect the incidence of thrombosis. However, it determines to a great degree the lateralization of the thrombus.

Entities:  

Mesh:

Year:  1975        PMID: 51062     DOI: 10.1007/bf00312543

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  29 in total

1.  Hypercoagulability associated with malignant disease and with the postoperative state. Evidence for elevated levels of antihemophilic globulin.

Authors:  M A AMUNDSEN; J A SPITTELL; J H THOMPSON; C A OWEN
Journal:  Ann Intern Med       Date:  1963-04       Impact factor: 25.391

2.  A morphologic study of pancreatic carcinoma with reference to multiple thrombi.

Authors:  C J LAFLER; D L HINERMAN
Journal:  Cancer       Date:  1961 Sep-Oct       Impact factor: 6.860

3.  Disseminated thrombosis in colon cancer.

Authors:  D G MCKAY; G H WAHLE
Journal:  Cancer       Date:  1955 Sep-Oct       Impact factor: 6.860

4.  Acute hemorrhagic syndrome with hypofibrinogenemia in metastatic cancer.

Authors:  P G FRICK
Journal:  Acta Haematol       Date:  1956-07       Impact factor: 2.195

5.  Multiple migratory thrombophlebitis associated with ovarian carcinoma.

Authors:  P H HENDERSON
Journal:  Am J Obstet Gynecol       Date:  1955-08       Impact factor: 8.661

6.  Venous thrombosis and obscure visceral carcinoma; report of ten cases.

Authors:  S PERLOW; J L DANIELS
Journal:  AMA Arch Intern Med       Date:  1956-02

7.  The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate.

Authors:  H J TAGNON; W F WHITMORE; P SCHULMAN; S C KRAVITZ
Journal:  Cancer       Date:  1953-01       Impact factor: 6.860

8.  A clinical study of elevated platelet adhesiveness and accelerated clot-retraction time.

Authors:  J P SAVITSKY; R WERMAN
Journal:  Am J Clin Pathol       Date:  1954-02       Impact factor: 2.493

9.  Nonbacterial thrombotic endocarditis in patients with malignant neoplastic diseases.

Authors:  P Rosen; D Armstrong
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

10.  Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli. A syndrome.

Authors:  R F Rohner; J T Prior; J H Sipple
Journal:  Cancer       Date:  1966-12       Impact factor: 6.860

View more
  18 in total

Review 1.  Bronchogenic adenocarcinoma presenting as a synchronous solitary lytic skull lesion with ischaemic stroke--case report and literature review.

Authors:  David O'Connell; Chandrasekaran Kaliaperumal; Gerald Wyse; Julie McCarthy; Aisling Ryan
Journal:  BMJ Case Rep       Date:  2011-12-20

2.  Haemostatic abnormalities in brain tumours.

Authors:  V P Singh; D Jain; R Mohan; R Bhatia; M Bhargava
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

3.  A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors.

Authors:  Michael B Streiff; Xiaobu Ye; Thomas S Kickler; Serena Desideri; Jayesh Jani; Joy Fisher; Stuart A Grossman
Journal:  J Neurooncol       Date:  2015-06-23       Impact factor: 4.130

4.  Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

Authors:  E W Jeffes; Y B Beamer; S Jacques; R S Silberman; B Vayuvegula; S Gupta; J S Coss; R S Yamamoto; G A Granger
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

5.  High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.

Authors:  Roger Henriksson; Annika Malmström; Per Bergström; Gertrud Bergh; Thomas Trojanowski; Lars Andreasson; Erik Blomquist; Sonny Jonsborg; Tomas Edekling; Pär Salander; Thomas Brännström; A Tommy Bergenheim
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

6.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile.

Authors:  R Sawaya; M Zuccarello; M Elkalliny; H Nishiyama
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

8.  Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial.

Authors:  H Ian Robins; Anne O'Neill; Mark Gilbert; Mark Olsen; Ronald Sapiente; Brian Berkey; Minesh Mehta
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-20       Impact factor: 3.333

9.  Thromboembolic phenomena in neurosurgical patients operated upon for primary and metastatic brain tumors.

Authors:  S Constantini; R Kornowski; S Pomeranz; Z H Rappaport
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

10.  Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas.

Authors:  Tene A Cage; Kathleen R Lamborn; Marcus L Ware; Anna Frankfurt; Lenna Chakalian; Mitchell S Berger; Michael W McDermott
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.